No Data
Jefferies Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $44
Cantor Fitzgerald Maintains Summit Therapeutics(SMMT.US) With Buy Rating
Express News | Goldman Sachs Maintains Buy on Summit Therapeutics, Raises Price Target to $41
Summit Therapeutics Analyst Ratings
Trending Stocks Today | Polyrizon Shoots up 217.71%